PURPOSE: A substantial part of rheumatoid arthritis (RA) patients is chronically treated with adalimumab. Some of these patients produce antibodies against adalimumab, which correlate with lower serum drug levels and reduced clinical response. Long term exposure to antigens may result in antigen specific IgG4 production as was demonstrated in studies on prolonged exposure to antigens such as different allergens, Factor VIII and IFN-β. Here, we investigate whether long term treatment of RA patients with the therapeutic monoclonal antibody adalimumab leads to the production of specific IgG4 antibodies. METHODS: We developed radio immunoassays to detect total IgG or IgG4 against adalimumab and applied these in a cohort of 271 consecutive RA patients during 3 years of adalimumab treatment. RESULTS: In 32 % of the 271 patients antibodies against adalimumab were detectable. IgG4 antibodies were detected in 29 % of the patients. The proportion IgG4 of total IgG against adalimumab varies widely between patients, and IgG4 was found to contribute significantly to the anti drug antibody (ADA) response in some patients. CONCLUSION: In the immune response against adalimumab in adalimumab-treated RA patients a considerable part of the ADA is IgG4. Although IgG4 is often considered to be harmless due to its lack of effector function, neutralization of adalimumab by IgG4 antibodies will lead to a reduced clinical response.
PURPOSE: A substantial part of rheumatoid arthritis (RA) patients is chronically treated with adalimumab. Some of these patients produce antibodies against adalimumab, which correlate with lower serum drug levels and reduced clinical response. Long term exposure to antigens may result in antigen specific IgG4 production as was demonstrated in studies on prolonged exposure to antigens such as different allergens, Factor VIII and IFN-β. Here, we investigate whether long term treatment of RApatients with the therapeutic monoclonal antibody adalimumab leads to the production of specific IgG4 antibodies. METHODS: We developed radio immunoassays to detect total IgG or IgG4 against adalimumab and applied these in a cohort of 271 consecutive RApatients during 3 years of adalimumab treatment. RESULTS: In 32 % of the 271 patients antibodies against adalimumab were detectable. IgG4 antibodies were detected in 29 % of the patients. The proportion IgG4 of total IgG against adalimumab varies widely between patients, and IgG4 was found to contribute significantly to the anti drug antibody (ADA) response in some patients. CONCLUSION: In the immune response against adalimumab in adalimumab-treated RApatients a considerable part of the ADA is IgG4. Although IgG4 is often considered to be harmless due to its lack of effector function, neutralization of adalimumab by IgG4 antibodies will lead to a reduced clinical response.
Authors: Daniel E Furst; Norman Gaylis; Vance Bray; Ewa Olech; David Yocum; Jeffrey Ritter; Michael Weisman; Daniel J Wallace; John Crues; Dinesh Khanna; Gregory Eckel; Newman Yeilding; Peter Callegari; Sudha Visvanathan; Jeannie Rojas; Ronald Hegedus; Laura George; Khalid Mamun; Keith Gilmer; Orrin Troum Journal: Ann Rheum Dis Date: 2007-04-05 Impact factor: 19.103
Authors: Geertje M Bartelds; Charlotte L M Krieckaert; Michael T Nurmohamed; Pauline A van Schouwenburg; Willem F Lems; Jos W R Twisk; Ben A C Dijkmans; Lucien Aarden; Gerrit Jan Wolbink Journal: JAMA Date: 2011-04-13 Impact factor: 56.272
Authors: Ajay Nirula; Scott M Glaser; Susan L Kalled; Frederick R Taylor; Frederick R Taylora Journal: Curr Opin Rheumatol Date: 2011-01 Impact factor: 5.006
Authors: Geertje M Bartelds; Carla A Wijbrandts; Michael T Nurmohamed; Steven Stapel; Willem F Lems; Lucien Aarden; Ben A C Dijkmans; Paul Peter Tak; Gerrit Jan Wolbink Journal: Ann Rheum Dis Date: 2007-02-14 Impact factor: 19.103
Authors: A M Witteman; S O Stapel; D H Sjamsoedin; H M Jansen; R C Aalberse; J S van der Zee Journal: Int Arch Allergy Immunol Date: 1996-04 Impact factor: 2.749
Authors: Jack L Arbiser; Michael Y Bonner; Nicole Ward; Justin Elsey; Shikha Rao Journal: Biochim Biophys Acta Gen Subj Date: 2018-05-28 Impact factor: 3.770
Authors: Fleur S van de Bovenkamp; Ninotska I L Derksen; Pleuni Ooijevaar-de Heer; Karin A van Schie; Simone Kruithof; Magdalena A Berkowska; C Ellen van der Schoot; Hanna IJspeert; Mirjam van der Burg; Ann Gils; Lise Hafkenscheid; René E M Toes; Yoann Rombouts; Rosina Plomp; Manfred Wuhrer; S Marieke van Ham; Gestur Vidarsson; Theo Rispens Journal: Proc Natl Acad Sci U S A Date: 2018-02-05 Impact factor: 11.205
Authors: Pauline A van Schouwenburg; Simone Kruithof; Christian Votsmeier; Karin van Schie; Margreet H Hart; Rob N de Jong; Esther E L van Buren; Marieke van Ham; Lucien Aarden; Gertjan Wolbink; Diana Wouters; Theo Rispens Journal: J Biol Chem Date: 2014-10-17 Impact factor: 5.157
Authors: Panagiotis Karagiannis; Amy E Gilbert; Debra H Josephs; Niwa Ali; Tihomir Dodev; Louise Saul; Isabel Correa; Luke Roberts; Emma Beddowes; Alexander Koers; Carl Hobbs; Silvia Ferreira; Jenny L C Geh; Ciaran Healy; Mark Harries; Katharine M Acland; Philip J Blower; Tracey Mitchell; David J Fear; James F Spicer; Katie E Lacy; Frank O Nestle; Sophia N Karagiannis Journal: J Clin Invest Date: 2013-04 Impact factor: 14.808